TALIS BIOMEDICAL CORP - COM NEW (TLIS)

CUSIP: 87424L207

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / COM NEW
Total 13F shares
792,526
Share change
-4,086
Total reported value
$6,934,526
Price per share
$8.75
Number of holders
18
Value change
-$20,723
Number of buys
7
Number of sells
5

Quarterly Holders Quick Answers

What is CUSIP 87424L207?
CUSIP 87424L207 identifies TLIS - TALIS BIOMEDICAL CORP - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of TALIS BIOMEDICAL CORP - COM NEW (TLIS) as of Q1 2024

As of 31 Mar 2024, TALIS BIOMEDICAL CORP - COM NEW (TLIS) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 792,526 shares. The largest 10 holders included BAKER BROS. ADVISORS LP, DME Capital Management, LP, BML Capital Management, LLC, VANGUARD GROUP INC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, PRELUDE CAPITAL MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., and Tower Research Capital LLC (TRC). This page lists 18 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.